The global demand for Late Stage Chronic Kidney Disease Therapeutics was valued at around USD 4.7 Billion in 2019. However, with rising prevalence of chronic kidney disease across the globe, the overall late stage kidney disease therapeutics market is anticipated to surpass USD 11.1 Billion in 2027 and forecast to grow at a prolific CAGR of around 11.6% throughout the forecast period (2022 to 2032)
| Report Attribute | Details |
|---|---|
| Late Stage Chronic Kidney Disease Therapeutics Market Projected Growth Rate (2022 to 2032) | 11.6% CAGR |
Chronic kidney disease (CKD) has been recognized as a leading public health problem worldwide due to its high morbidity and mortality rates. This fatal disease is usually caused by diabetes mellitus, hypertension, obesity, and aging.
Late stage chronic disease is an advanced stage of chronic renal disease where kidneys no longer function or work. This reduces the chances of survival and therefore requires proper treatment approaches including kidney transplant, dialysis and therapeutics. Among these, kidney transplant and dialysis are the only two effective treatments for CKD. However, dialysis is often costly and transplantation is limited by organ shortage. This has brought late stage chronic kidney disease therapeutics market into the spotlight.
Majority of the people with lower socioeconomic status and limited access to treatments are highly dependent on late stage chronic kidney disease therapeutics. These therapeutics can also be used in combination with dialysis.
Late stage chronic kidney disease therapeutics are drugs used for the treatment of late-stage chronic kidney disease induced hyperkalemia, hyperphosphatemia, hyperparathyroidism. Consumption of late stage chronic kidney disease therapeutics help to relieve the symptoms of CKD, delay late stage chronic kidney disease development, and thus enable patients to live longer lives without going through dialysis or transplantation.
Rising prevalence of chronic kidney disease (CKD) worldwide, rising awareness among people regarding the benefits of late stage chronic kidney disease therapeutics, introduction of favorable reimbursement policies for CKD treatment, higher diagnostic rates, and development of new effective therapeutics are some of the major factors expected to boost the growth of late stage chronic kidney disease therapeutics market during the forecast period.
Increasing incidence of chronic kidney disease is perhaps the major factor behind the robust expansion of late stage chronic disease therapeutics market. According to a report published in the Lancet, global prevalence of chronic kidney diseases reached around 700 million in 2017 and the numbers are expected to further surge during the upcoming years.
Similarly, the introduction of new advanced late stage kidney disease therapeutics along with poor access to renal replacement therapy and dialysis in developing countries is expected to favor market growth during the assessment period.
Despite its optimistic stance, the late stage chronic kidney disease therapeutics market is facing various obstacles that are restraining its growth to some extent. Some of these growth restraining factors are the delay in the diagnosis of CKD and increase in the number of kidney transplants.
Similarly, various side effects associated with late stage chronic kidney disease therapeutics is also limiting market growth.
According to Future Market Insights, North America accounted for the largest share of the global late stage chronic kidney disease therapeutics market in 2021 and is projected to grow at the fastest CAGR over the forecast period. Growth in the market is attributable to the rising incidence of chronic kidney disease, availability of favorable reimbursement policies, and heavy presence of leading market players.
Demand for late stage chronic kidney disease therapeutics is particularly high across the United States due to surge in chronic kidney disease cases and easy availability of advanced therapeutics. According to the Centers for Disease Control and Prevention (CDC), around 37 million people in the United States are estimated to have chronic kidney disease.
The Asia Pacific late stage chronic kidney disease therapeutics market is anticipated to grow at a considerable pace during the forecast period between 2022 and 2032, owing to the rising health awareness, growing prevalence of chronic kidney disease, and increasing government initiatives and investments to reduce the burden of chronic kidney disease.
According to the National Kidney Foundation, number of cases of kidney failure is expected to surge rapidly in developing countries, such as China and India, where the number of elderly people is increasing. This will generate lucrative growth prospects within the Asia Pacific late stage chronic kidney disease therapeutics market during the forecast period.
Some of the key participants present in the global late stage chronic kidney disease therapeutics market includes Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, Spectrum, Mitsubishi Tanabe, OPKO Health, Relypsa, Shield Therapeutics, Shire, Vifor and ZS Pharma among others.
These leading players are continuously investing in research and development to introduce more effective therapeutics. Besides this, they are partnering and collaborating with dialysis centers to increase their sales and gain a competitive edge in the market.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 11.6% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Product Type, Indication, End Users, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; APEJ; Japan; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
| Key Companies Profiled | Amgen; Deltanoid; AbbVie; Sanofi; Ardelyx; AstraZeneca; Kyowa Hakko Kirin; Genzyme, Keryx; Spectrum; Mitsubishi Tanabe; OPKO Health; Relypsa; Shield Therapeutics; Shire; Vifor; ZS Pharma |
| Customization | Available Upon Request |
Table 1: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 3: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 4: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 5: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 6: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 7: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 8: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 9: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 10: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 11: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 12: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 13: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 15: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 16: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 17: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 18: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 19: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 20: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 21: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 23: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 24: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 25: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 26: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 27: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 28: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Figure 1: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 2: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032
Figure 3: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 4: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Region, 2022-2032
Figure 5: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 6: Global Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 9: Global Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 10: Global Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 11: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 12: Global Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 13: Global Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 14: Global Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 15: Global Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 16: Global Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 17: Global Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032
Figure 18: Global Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032
Figure 19: Global Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 20: Global Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Region, 2022-2032
Figure 21: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 22: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032
Figure 23: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 24: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 26: North America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 29: North America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 30: North America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 31: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 32: North America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 33: North America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 34: North America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 35: North America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 36: North America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 37: North America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032
Figure 38: North America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032
Figure 39: North America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 40: North America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 42: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032
Figure 43: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 44: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 46: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 49: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 50: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 51: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 52: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 53: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 54: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 55: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 56: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 57: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032
Figure 58: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032
Figure 59: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 60: Latin America Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032
Figure 61: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 62: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032
Figure 63: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 64: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 66: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 69: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 70: Europe Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 71: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 72: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 73: Europe Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 74: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 75: Europe Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 76: Europe Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 77: Europe Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032
Figure 78: Europe Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032
Figure 79: Europe Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 80: Europe Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032
Figure 81: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 82: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032
Figure 83: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 84: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 85: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 86: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 89: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 90: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 91: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 92: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 93: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 94: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 95: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 96: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 97: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032
Figure 98: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032
Figure 99: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 100: East Asia Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032
Figure 101: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 102: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032
Figure 103: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 104: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 105: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 106: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 109: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 110: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 111: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 112: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 113: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 114: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 115: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 116: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 117: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032
Figure 118: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032
Figure 119: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 120: South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032
Figure 121: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 122: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Indication, 2022-2032
Figure 123: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 124: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 125: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 126: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 127: MEA Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 128: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 129: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 130: MEA Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 131: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 132: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 133: MEA Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 134: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 135: MEA Late Stage Chronic Kidney Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 136: MEA Late Stage Chronic Kidney Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 137: MEA Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Drug Class, 2022-2032
Figure 138: MEA Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Indication, 2022-2032
Figure 139: MEA Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 140: MEA Late Stage Chronic Kidney Disease Therapeutics Market Attractiveness by Country, 2022-2032
FMI projects the global late stage chronic kidney disease therapeutics market to expand at a stupendous CAGR of around 11.6% through 2032.
North America is forecast to remain the most lucrative market for late stage chronic kidney disease therapeutics during the assessment period.
Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, and Spectrum are some prominent late stage chronic kidney disease therapeutics manufacturers
Explore Similar Insights
Late Stage Chronic Kidney Disease Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
